Non-Small Cell Lung Cancer Stage
Conditions
Keywords
Non-small cell lung cancer, Platinum doublet chemotherapy, Neoadjuvant
Brief summary
The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
Detailed description
Open-label, single-arm multi-center phase II trial of neoadjuvant Compound 121564 plus platinum doublet chemotherapy conducted among patients with early stage (IB, II, IIIA) non-small cell lung cancer.
Interventions
DRUGCompound 121564
Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
Sponsors
Merck KGaA, Darmstadt, Germany
Phoenix Clinical Research
Arafat Tfayli
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males and females aged ≥ 18 years. 2. Histologically confirmed NSCLC (squamous and non-squamous). 3. High-risk stage IB (tumor ≥ 4 cm in size, or grade 3, or with visceral pleura involvement), II or IIIA disease. 4. Have biopsy tissue available (fresh and archived) for PD-L1 and correlative studies testing prior to therapy. 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\. 6) Have a life expectancy of ≥ 6 months. 7) No previous systemic anticancer therapy or surgical resection for his or her NSCLC. 8) Subject has voluntarily agreed to participate by giving written informed consent for the trial. 9) Subject must be willing and able to comply with scheduled visits, treatment schedule and laboratory testing. 10) Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to receiving the first dose of study medication. 11) Females should not be breastfeeding. 12) Female subjects of childbearing potential as well as males sexually active with women of childbearing potential must be willing to use an adequate method of contraception. 13) Have pulmonary and cardiac function testing deemed adequate for thoracic surgical intervention. 14) Have adequate organ function by meeting the following: 1. Absolute neutrophil count (ANC) ≥1,500/mcL. 2. Platelets ≥100,000/mcL. 3. Hemoglobin ≥9 g/dL. 4. Serum creatinine ≤1.5 X upper limit of normal (ULN) OR calculated creatinine clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subjects with creatinine levels \> 1.5 X institutional ULN. 5. Serum total bilirubin ≤ ULN. 6. AST (SGOT) and ALT (SGPT) ≤ 1.5 X ULN. 7. Alkaline phosphatase ≤ 2.5 X ULN. 8. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. 9. Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy.
Exclusion criteria
1. Subject deemed unfit for surgery (by pulmonary or cardiac assessment). 2. Subject with known autoimmune disease that has required systemic therapy in the last 2 years. 3. Prior organ transplantation including allogenic stem-cell transplantation. 4. Clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. 5. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade \> 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable. 6. Subject on immunosuppressive therapy or corticosteroids within 14 days prior to starting study drugs. 7. Subject with interstitial lung disease that is symptomatic or history of pneumonitis that required oral or systemic glucocorticoids to manage. 8. Subject must have recovered from the effects of major surgery or significant trauma at least 14 days prior to therapy. 9. Subject with previous malignancies are excluded unless complete remission was achieved at least 2 years prior to therapy. 10. Other active malignancy requiring concurrent intervention. 11. Subject with active infection requiring systemic therapy. 12. Subject with known history of testing positive for human immunodeficiency virus (HIV) or known to have acquired immunodeficiency syndrome (AIDS). 13. Subject has known active hepatitis B or C. 14. Vaccination within 4 weeks of the first dose of Compound 121564 and while on trials is prohibited except for administration of inactivated vaccines. 15. Subject is pregnant or breastfeeding. 16. Subject has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 17. Subject previously had a severe hypersensitivity reaction to any of the study drugs. 18. Subject is currently participating and receiving study therapy from another clinical trial. 19. Subject had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. 20. Patient who is not willing to sign the consent form. 21. Legal incapacity or limited legal capacity patients receiving other oncology specific medication not authorized in the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria | At week 9 | To assess the overall response rate (ORR) of patients receiving neoadjuvant Compound 121564 plus platinum doublet chemotherapy based on RECIST 1.1 criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major pathologic response rate (<10% viable tumor cells) | At 12 weeks | To assess the major pathologic response rate (\<10% viable tumor cells) in patients receiving combination Compound 121564 and chemotherapy. |
| Progression-Free Survival (PFS) | At 1, 2 and 3 years | To assess progression-free survival (PFS) at 1, 2 and 3 years in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy. |
| Overall Survival (OS) | At 1, 2 and 3 years | To assess overall survival (OS) in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy. |
| Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in enrolled squamous vs. non-squamous lung cancer patients | At week 9 | To compare the ORR in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen. |
| Progression-Free Survival (PFS) in enrolled squamous vs. non-squamous lung cancer patients | At 1, 2 and 3 years | To compare the PFS in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen. |
| Pathologic complete response rate | At 12 weeks | To assess the pathologic complete response rate in patients receiving combination Compound 121564 and chemotherapy. |
| Patient-related outcomes Quality of Life assessment using the questionnaire for functional assessment of cancer therapy for patients with lung cancer (FACT-L version 4) | At week 9 | To assess patient-related outcomes in patients receiving a combination of Compound 121564 plus platinum doublet chemotherapy. |
| Number of participants with treatment-related adverse events as assessed by CTCAE v 4.0 | With every administration | To assess the tolerability of the proposed treatment regimen in the cohort of patient enrolled. |
| Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1 | At week 9 | To analyze as exploratory analysis the ORR in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen. |
| Progression-Free Survival (PFS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1 | At 1, 2 and 3 years | To analyze as exploratory analysis the PFS in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen. |
| Overall Survival (OS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1 | At 1, 2 and 3 years | To analyze as exploratory analysis the OS in patients with 50% or more PD-L1 expression level vs. patients with less than 50% PD-L1 expression level receiving the proposed treatment regimen. |
| Overall Survival (OS) in enrolled squamous vs. non-squamous lung cancer patients | At 1, 2 and 3 years | To compare the OS in enrolled squamous vs. non-squamous lung cancer patients receiving the proposed treatment regimen. |
Countries
Jordan, Lebanon
Contacts
Primary ContactArafat H Tfayli, MD
Outcome results
None listed